

Supplemental materials for





Anticancer profile of rhodanines: structure-activity relationship (SAR) and molecular targets. A review





Jacek Szczepański, Helena Tuszevska and Nazar Trotsko *




Chair and Department of Organic Chemistry, Faculty of Pharmacy, Medical University of
Lublin, 4a Chodźki Street, 20-093 Lublin, Poland; jaacek.szczepanski.93@gmail.com
(J.S.); tuszevska.helena93@gmail.com (H.T.); nazar.trotsko@umlub.pl (N.T.)




* Correspondence: nazar.trotsko@umlub.pl (N.T.); Tel.: +48 81 448 7244




Table S1. The most potent 3-or 5-substituted, and 3,5-disubstituted rhodanine derivatives as anticancer agents





Nr.	Structure	Cell lines	IC ₅₀ , % inhibition	References
1		MCF-7	64.4%	[25]
2		K-562	14.6 µg/mL	[26]
3		K-562, HeLa	11.1 µg/mL, < 200 µg/mL	[25,26]
4		HCT 116	10 µM	[28]





5		MDA-MB231, HCT 116, Caco 2	2 μ M, 2 μ M, 3 μ M	[28]
6		A549	43.6 μ M	[12]
7		CCRF-CEM/L	56.34%	[29]
8		T-47D/BC	76.91%	[29]




9		HeLa, HT29, A549, MCF-7	28.3 μ M, 24.5 μ M, 26.6 μ M, 28.6 μ M	[11]
10		HGC, DU-145, MCF-7	7.2 μ M, 15.3 μ M, 9.5 μ M	[30]
11		MCF-7	7.67 μ g/mL	[34]




12		MCF-7	11.7 $\mu\text{g/mL}$	[34]
13		HL-60, A549, Raji, MDA-MB201	2.66 μM , 5.31 μM , 4.48 μM , 6.42 μM	[35]
14		HL-60, A549, Raji, MDA-MB201	8.42 μM , > 50 μM , 25.48 μM , 21.33 μM	[35]





15		HT-1080, HL-60, K-562, AG01523	8.7 μM , 1.2 μM , 1.5 μM , > 100 μM	[36]
16		CCRF-CEM, RPMI-8226, HOP-92, Normal human cell line	GI ₅₀ = 2.50 μM , GI ₅₀ = 2.52 μM , GI ₅₀ = 0.62 μM , LC ₅₀ > 100 μM	[32]
17		HeLa S3, Hep G2	EC ₅₀ = 7.9 μM , EC ₅₀ = 6.1 μM	[33]





18		HGC, MNK-74	11.2 μ M, 13.9 μ M	[30]
19		MCF-7	81%	[36]
20		MCF-7	77%	[36]
21		MCF-7	71%	[36]





22		A549	CTC ₅₀ = 3.6 µg/mL	[37]
23		Huh7 D12, Caco 2	8 µM, 8 µM	[13]
24		MCF-7	82.5%	[25]
25		A549, H460, HT29	0.8 µM, 1.3 µM, 2.8 µM	[12]



26		A549, H460, HT29	3.1 μ M, 0.3 μ M, 2.8 μ M	[12]
27		Huh7, MCF-7	4.67 μ M, 2.30 μ M	[38]
28		MCF-7, MDA-MB-231, Huh7	EC ₅₀ = 1.732 μ M, EC ₅₀ = 2.912 μ M, EC ₅₀ = 3.797 μ M	[39]

29		panel of approximately sixty cancer cell lines ¹	GP mean= 22.40%	[10]
30		panel of approximately sixty cancer cell lines ¹	GP mean= 99.30%	[10]
31		HL-60, MDA-MB-201, Raji, A549	0.21 μ M, 0.33 μ M, 1.23 μ M, 2.67 μ M	[35]

32		HL-60, MDA-MB-201, Raji, A549	0.77 μ M, 1.22 μ M, 1.79 μ M, 5.68 μ M	[35]
33		HeLa	52.00%	[27]
34		Huh7 D12, HaCat, MDA-MB231, normal fibroblasts	9 μ M, 8 μ M, 9 μ M, > 25 μ M	[40]
35		Dami	35.10%	[41]

36		Dami, HL-60	44.75%, 40.30%	[41]
37		A2780, A2780cisR	4.4 nM, 3.3 nM	[42]
38		K562, K562	8.79 µg/mL - T.B. assay, 19.62 µg/mL - MTT assay	[43]
39		60 tumor cell lines MG_MID ²	GI ₅₀ = 1.57 µM	[44]

40		60 tumor cell lines MG_MID ²	GI ₅₀ = 2.8 μM	[44]
41		60 tumor cell lines MG_MID ²	GI ₅₀ = 4.79 μM	[44]
42		60 tumor cell lines MG_MID	GI ₅₀ = 18 μM	[44]
43		A549, NRK-52E	7 μM, 14.7 μM	[46]

44		BT-549/BC	67.36%	[29]
45		IGROV1/OC	82.21%	[29]

MG_MID - mean graph midpoint, arithmetical mean value for all tested cell lines.

^{1,2} panel of approximately sixty cancer cell lines and 60 tumor cell lines MG_MID the next cell lines were used: leukemia (CCRF-CEM, HL-60, K562, MOLT-4, RPMI-8226, SR), NSC lung cancer (A549, EKVX, HOP-62, HOP-92, NCI-H266, NCI-H23, NCI-H322M, NCI-H460, NCI-H522), colon cancer (COLO 205, HCT 116, HCT-15, HT29, KM12, SW-620, HCC-2998), CNS cancer (SF-268, SF-295, SF-539, SNB-19, SNB-75, U251), melanoma (LOX IMVI, MALME-3M, M14, MDA-MB-435, UACC-62, UACC-257, SK-MEL-2, SK-MEL-5, SK-MEL-28), ovarian cancer (IGROVI, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, NCI/ADR-RES, SK-OV-3), renal cancer (786-0, A498, ACHN, CAKI-1, RXF 393, SN12C, TK-10, UO-31), prostate cancer (PC-3, DU-145), breast cancer (MCF-7, MDA-MB-231, HS 578T, BT-549, T-47D, MDA-MB-468).